Interleukin‐33/ST2 axis promotes breast cancer growth and metastases by facilitating intratumoral accumulation of immunosuppressive and innate lymphoid cells
暂无分享,去创建一个
N. Arsenijević | M. Milovanovic | M. Lukic | N. Pejnović | I. Jovanovic | G. Radosavljević | Jelena M. Pantić
[1] Lianfeng Zhang,et al. Transgenic expression of IL-33 activates CD8(+) T cells and NK cells and inhibits tumor growth and metastasis in mice. , 2013, Cancer letters.
[2] N. Arsenijević,et al. Deletion of IL-33R (ST2) Abrogates Resistance to EAE in BALB/C Mice by Enhancing Polarization of APC to Inflammatory Phenotype , 2012, PloS one.
[3] G. Shurin,et al. Tumor associated regulatory dendritic cells. , 2012, Seminars in cancer biology.
[4] W. Stetler-Stevenson,et al. TIMP-2 Targets Tumor-associated Myeloid Suppressor Cells With Effects in Cancer Immune Dysfunction and Angiogenesis , 2012, Journal of immunotherapy.
[5] J. Papadimitriou,et al. Full-Length IL-33 Promotes Inflammation but not Th2 Response In Vivo in an ST2-Independent Fashion , 2012, The Journal of Immunology.
[6] Fumio Takei,et al. Lung natural helper cells are a critical source of Th2 cell-type cytokines in protease allergen-induced airway inflammation. , 2012, Immunity.
[7] S. Nakae,et al. The Alarmin Interleukin-33 Drives Protective Antiviral CD8+ T Cell Responses , 2012, Science.
[8] K. Tsuneyama,et al. Identification of Innate IL-5–Producing Cells and Their Role in Lung Eosinophil Regulation and Antitumor Immunity , 2012, The Journal of Immunology.
[9] Richard T. Lee,et al. Interleukin 33 as a Mechanically Responsive Cytokine Secreted by Living Cells* , 2012, The Journal of Biological Chemistry.
[10] K. Ohuchida,et al. Significance of combination therapy of zoledronic acid and gemcitabine on pancreatic cancer , 2012, Cancer science.
[11] N. Arsenijević,et al. Protective role of IL-33/ST2 axis in Con A-induced hepatitis. , 2012, Journal of hepatology.
[12] K. Isse,et al. IL-33 Expands Suppressive CD11b+ Gr-1int and Regulatory T Cells, including ST2L+ Foxp3+ Cells, and Mediates Regulatory T Cell-Dependent Promotion of Cardiac Allograft Survival , 2011, The Journal of Immunology.
[13] G. Coukos,et al. The parallel lives of angiogenesis and immunosuppression: cancer and other tales , 2011, Nature Reviews Immunology.
[14] L. Zitvogel,et al. IL-18 induces PD-1-dependent immunosuppression in cancer. , 2011, Cancer research.
[15] D. Stocken,et al. Elevated myeloid-derived suppressor cells in pancreatic, esophageal and gastric cancer are an independent prognostic factor and are associated with significant elevation of the Th2 cytokine interleukin-13 , 2011, Cancer Immunology, Immunotherapy.
[16] Qiwen Ben,et al. Serum Interleukin-33 Levels in Patients with Gastric Cancer , 2011, Digestive Diseases and Sciences.
[17] S. Jonjić,et al. ST2 deletion enhances innate and acquired immunity to murine mammary carcinoma , 2011, European journal of immunology.
[18] S. Koyasu,et al. Type 2 innate immune responses and the natural helper cell , 2011, Immunology.
[19] J. D. Di Santo,et al. IL‐1β regulates a novel myeloid‐derived suppressor cell subset that impairs NK cell development and function , 2010, European journal of immunology.
[20] T. Abe,et al. IL-33 is a crucial amplifier of innate rather than acquired immunity , 2010, Proceedings of the National Academy of Sciences.
[21] Ashley M. Miller,et al. Interleukin-33 Induces Protective Effects in Adipose Tissue Inflammation During Obesity in Mice , 2010, Circulation research.
[22] A. McKenzie,et al. Nuocytes represent a new innate effector leukocyte that mediates type-2 immunity , 2010, Nature.
[23] I. McInnes,et al. Disease-associated functions of IL-33: the new kid in the IL-1 family , 2010, Nature Reviews Immunology.
[24] 茂呂 和世. Innate production of T[H]2 cytokines by adipose tissue-associated c-Kit[+]Sca-1[+] lymphoid cells , 2010 .
[25] Tsutomu Takeuchi,et al. Innate production of TH2 cytokines by adipose tissue-associated c-Kit+Sca-1+ lymphoid cells , 2009, Nature.
[26] H. Matsushima,et al. IL‐33 promotes DC development in BM culture by triggering GM‐CSF production , 2009, European journal of immunology.
[27] I. McInnes,et al. IL-33 Amplifies the Polarization of Alternatively Activated Macrophages That Contribute to Airway Inflammation1 , 2009, The Journal of Immunology.
[28] Bo-Jeong Pyun,et al. Interleukin-33 induces angiogenesis and vascular permeability through ST2/TRAF6-mediated endothelial nitric oxide production. , 2009, Blood.
[29] S. Briest,et al. Breast cancer lung metastasis requires expression of chemokine receptor CCR4 and regulatory T cells. , 2009, Cancer research.
[30] J. Girard,et al. The IL-1-like cytokine IL-33 is inactivated after maturation by caspase-1 , 2009, Proceedings of the National Academy of Sciences.
[31] P. Gourdy,et al. The pro‐Th2 cytokine IL‐33 directly interacts with invariant NKT and NK cells to induce IFN‐γ production , 2009, European journal of immunology.
[32] Michelle Collazo,et al. Subsets of Myeloid-Derived Suppressor Cells in Tumor-Bearing Mice1 , 2008, The Journal of Immunology.
[33] M. Teixeira,et al. IL-33 Induces Antigen-Specific IL-5+ T Cells and Promotes Allergic-Induced Airway Inflammation Independent of IL-41 , 2008, The Journal of Immunology.
[34] I. McInnes,et al. IL-33 exacerbates antigen-induced arthritis by activating mast cells , 2008, Proceedings of the National Academy of Sciences.
[35] Ashley M. Miller,et al. IL-33 reduces the development of atherosclerosis , 2008, The Journal of experimental medicine.
[36] R. Kastelein,et al. IL-1 Receptor Accessory Protein and ST2 Comprise the IL-33 Receptor Complex , 2007, The Journal of Immunology.
[37] K. Tanabe,et al. Functional roles of immature dendritic cells in impaired immunity of solid tumour and their targeted strategies for provoking tumour immunity , 2006, Clinical and experimental immunology.
[38] C. Divino,et al. Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. , 2006, Cancer research.
[39] J Fernando Bazan,et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. , 2005, Immunity.
[40] Mitch Dowsett,et al. Proliferation marker Ki-67 in early breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[41] L. Zitvogel,et al. Natural killer cell–dendritic cell crosstalk in the initiation of immune responses , 2005, Expert opinion on biological therapy.
[42] Hans-Gustaf Ljunggren,et al. Impact of FASL-induced apoptosis in the elimination of tumor cells by NK cells. , 2005, Molecular immunology.
[43] H. Yamamura,et al. Immature tumor angiogenesis in high-grade and high-stage renal cell carcinoma. , 2003, Urology.
[44] G. Landman,et al. Tumour‐associated tissue eosinophilia as a prognostic factor in oral squamous cell carcinomas , 2002, Histopathology.
[45] Thomas D. Schmittgen,et al. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.
[46] D. Umetsu,et al. Pulmonary dendritic cells producing IL-10 mediate tolerance induced by respiratory exposure to antigen , 2001, Nature Immunology.
[47] D. J. Matthews,et al. T1/St2-Deficient Mice Demonstrate the Importance of T1/St2 in Developing Primary T Helper Cell Type 2 Responses , 2000, The Journal of experimental medicine.
[48] A. Ohta,et al. The critical role of Th1-dominant immunity in tumor immunology , 2000, Cancer Chemotherapy and Pharmacology.
[49] H. Nielsen,et al. Independent prognostic value of eosinophil and mast cell infiltration in colorectal cancer tissue , 1999, The Journal of pathology.
[50] Andreas Radbruch,et al. T1/ST2 is preferentially expressed on murine Th2 cells, independent of interleukin 4, interleukin 5, and interleukin 10, and important for Th2 effector function. , 1998, Proceedings of the National Academy of Sciences of the United States of America.